Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects

被引:14
|
作者
Tsukahara, Kengo [1 ]
Kimura, Kazuo [1 ]
Morita, Satoshi [1 ]
Ebina, Toshiaki [1 ]
Kosuge, Masami [1 ]
Hibi, Kiyoshi [1 ]
Iwahashi, Noriaki [1 ]
Endo, Mitsuaki [1 ]
Maejima, Nobuhiko [1 ]
Sugano, Teruyasu [1 ]
Umemura, Satoshi [1 ]
机构
[1] Yokohama City Univ, Med Ctr, Div Cardiol, Minami Ku, Yokohama, Kanagawa 2320024, Japan
关键词
Platelet inhibitors; Drug interactions; Coronary artery disease; PERCUTANEOUS CORONARY INTERVENTION; ELUTING STENT THROMBOSIS; PLATELET REACTIVITY; INCREASED RISK; CLOPIDOGREL RESISTANCE; CARDIOVASCULAR EVENTS; HEALTHY-SUBJECTS; THERAPY; ASPIRIN; RESPONSIVENESS;
D O I
10.1016/j.jjcc.2011.01.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although there has been an intense debate whether concomitant use of proton-pump inhibitors (PPIs) attenuates the antiplatelet effects of thienopyridine derivatives, the drug drug interaction remains unclear in Japanese patients with coronary artery disease. Methods and results: Platelet function test was performed in 461 patients who were scheduled for or had undergone stent implantation, treated with 100 mg/day of aspirin and a thienopyridine (200 mg/day of ticlopidine or 75 mg/day of clopidogrel) for at least 14 days. Adenosine diphosphate-induced platelet aggregation was evaluated with screen filtration pressure method, and the upper quartile of high platelet reactivity was defined as high on-treatment platelet reactivity (HPR). PPI use was at physician's discretion. Patients taking a thienopyridine plus a PPI (n = 166) were older and had a higher incidence of acute coronary syndromes on admission compared with patients taking a thienopyridine without a PPI (n = 295). The rate of HPR was higher in patients taking a thienopyridine plus a PPI than in patients taking a thienopyridine without a PPI (31% vs 21%, p=0.01). On multivariate logistic regression analysis, independent predictors of HPR were concomitant PPI use [odds ratio (OR): 1:66, 95% confidence interval (CI): 1.03-2.68], diabetes mellitus (OR: 1.76, CI: 1.11-2.81), and calcium channel blockers use (OR: 1.93, CI: 1.18-3.18). However, there was no significant difference in the rate of extremely high platelet reactivity [58 patients (12.5%) with PATI <4.0 mu M] between patients treated with a thienopyridine plus a PPI and those without a PPI (14% vs 11%, NS). Conclusion: HPR was frequently observed in Japanese patients treated with thienopyridines plus PPIs compared to those without PPIs. Further prospective studies are needed to estimate the risk of adverse cardiovascular events associated with concomitant use of PPIs and thienopyridines. (C) 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:275 / 282
页数:8
相关论文
共 50 条
  • [41] Safety of Concomitant Use of Proton Pump Inhibitors and Clopidogrel
    Khawaja, Owais
    Al-Mallah, Mouaz H.
    AMERICAN JOURNAL OF MEDICINE, 2010, 123 (04): : E11 - E11
  • [42] Concomitant use of proton-pump inhibitors with clopidogrel may increase risk for readmission after discharge for acute MI
    Juurlink, D.
    ANNALS OF INTERNAL MEDICINE, 2009, 151 (04)
  • [43] Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Recurrent Stroke and Myocardial Infarction
    Lee, Yong Kang
    Lim, Hyun Sun
    Choi, Youn, I
    Choe, Eun Ju
    Kim, Seonji
    You, Seng Chan
    Lee, Kyung Joo
    Kim, Yerim
    Park, Da Hee
    Shin, Woon Geon
    Seo, Seung In
    PHARMACEUTICALS, 2023, 16 (09)
  • [44] Defining Appropriate Use of Proton-Pump Inhibitors Among Medical Inpatients
    Pappas, Matt
    Jolly, Sanjay
    Vijan, Sandeep
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2016, 31 (04) : 364 - 371
  • [45] Review article: the long-term use of proton-pump inhibitors
    Raghunath, AS
    O'Morain, C
    Mcloughlin, RC
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 : 55 - 63
  • [46] Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors A Cohort Study
    Ray, Wayne A.
    Murray, Katherine T.
    Md, Marie R. Griffin
    Chung, Cecilia P.
    Smalley, Walter E.
    Hall, Kathi
    Daugherty, James R.
    Kaltenbach, Lisa A.
    Stein, C. Michael
    ANNALS OF INTERNAL MEDICINE, 2010, 152 (06) : 337 - +
  • [47] Defining Appropriate Use of Proton-Pump Inhibitors Among Medical Inpatients
    Matt Pappas
    Sanjay Jolly
    Sandeep Vijan
    Journal of General Internal Medicine, 2016, 31 : 364 - 371
  • [48] Use of Proton-Pump Inhibitors in Early Pregnancy and the Risk of Birth Defects
    Pasternak, Bjorn
    Hviid, Anders
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2011, 66 (04) : 195 - 197
  • [49] Concomitant use of proton-pump inhibitors with clopidogrel may increase risk for readmission after discharge for acute MI Commentary
    Granger, Christopher B.
    ANNALS OF INTERNAL MEDICINE, 2009, 151 (04)
  • [50] Proton-pump inhibitors: understanding the complications and risks
    Malfertheiner, Peter
    Kandulski, Arne
    Venerito, Marino
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (12) : 697 - 710